Drug intelligence / Profile preview

acoradine

Development stage: Phase 3
Lead developer: BridgeBio Pharma
Modality: Small Molecules

Overview

Acoradine is a drug currently under investigation for its potential use in treating unresectable hepatocellular carcinoma. While specific details regarding its precise chemical structure and mechanism of action are not readily available, it is likely an acridine derivative. Acridine derivatives are known for their anticancer properties, primarily through mechanisms such as DNA intercalation, inhibition of topoisomerases, telomerase inhibition, and inhibition of protein kinases.

Targets

TOP2A (DNA topoisomerase II)PK (Pyruvate kinase)DNATERT (Telomerase)

Beyond the preview

Go deeper on acoradine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acoradine.

Explore the full profile